| 51 |
32923400 | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. | 2020 |
3 |
| 52 |
32988879 | Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes. | 2020 Oct |
1 |
| 53 |
33469513 | Nuclear ING3 Expression Is Correlated With a Good Prognosis of Breast Cancer. | 2020 |
1 |
| 54 |
30764626 | Is There a Benefit of HER2-Positive Breast Cancer Subtype Determination in Clinical Practice? | Winter 2019 |
1 |
| 55 |
30922362 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. | 2019 Mar 29 |
1 |
| 56 |
31196969 | Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability. | 2019 Aug |
1 |
| 57 |
31340938 | Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. | 2019 Nov 1 |
2 |
| 58 |
31358837 | High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer. | 2019 Jul 29 |
1 |
| 59 |
31432367 | Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. | 2019 Nov |
1 |
| 60 |
31611907 | Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner. | 2019 |
1 |
| 61 |
31827586 | Molecular Subtypes Recognition of Breast Cancer in Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging Phenotypes from Radiomics Data. | 2019 |
1 |